Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Veerendra Munugalavadla
Observed names:
Munugalavadla, Veerendra,
V Munugalavadla,
V. Munugalavadla
Observed institutions:
Genentech,
Gilead Sciences (United States),
AstraZeneca (Canada),
AstraZeneca (United States),
Indiana University Indianapolis,
Indiana University School of Medicine,
Acerta Pharma BV (Netherlands),
Indiana University – Purdue University Indianapolis
show all 8
ORCID:
0000-0002-2390-3822
Observed ORCID:
0000-0002-2390-3822
OpenAlex ID:
A5050633601
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
2020
·
Jeff P Sharman
, Miklos Egyed
, et al.
·
The Lancet
·
632
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
2022
·
Jeff P. Sharman
, Miklos Egyed
, et al.
·
Leukemia
·
210
Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor
2005
·
Rebecca J. Chan
, Melissa B. Leedy
, et al.
·
Blood
·
156
Role of c-Kit and erythropoietin receptor in erythropoiesis
2005
·
Veerendra Munugalavadla
, Reuben Kapur
·
Critical Reviews in Oncology/Hematology
·
128
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025
·
Jennifer R. Brown
, John F. Seymour
, et al.
·
New England Journal of Medicine
·
127
Repression of c-Kit and Its Downstream Substrates by GATA-1 Inhibits Cell Proliferation during Erythroid Maturation
2005
·
Veerendra Munugalavadla
, Louis C. Dore
, et al.
·
Molecular and Cellular Biology
·
110
Rho Kinase Regulates the Survival and Transformation of Cells Bearing Oncogenic Forms of KIT, FLT3, and BCR-ABL
2011
·
Raghuveer Singh Mali
, Baskar Ramdas
, et al.
·
Cancer Cell
·
99
PDF
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
2020
·
Michael Overman
, Milind Javle
, et al.
·
Journal for ImmunoTherapy of Cancer
·
94
PDF
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia
2020
·
Jennifer A. Woyach
, James S. Blachly
, et al.
·
Cancer Discovery
·
79
p85α subunit of class IA PI-3 kinase is crucial for macrophage growth and migration
2005
·
Veerendra Munugalavadla
, Jovencio Borneo
, et al.
·
Blood
·
66
PDF
Regulation of Th2 Cytokine Expression in NKT Cells: Unconventional Use of Stat6, GATA-3, and NFAT2
2006
·
Zheng-Yu Wang
, Saritha Kusam
, et al.
·
The Journal of Immunology
·
63
PDF
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
2019
·
Jeff P. Sharman
, Versha Banerji
, et al.
·
Blood
·
62
c-Kit-Mediated Overlapping and Unique Functional and Biochemical Outcomes via Diverse Signaling Pathways
2004
·
Li Hong
, Veerendra Munugalavadla
, et al.
·
Molecular and Cellular Biology
·
61
Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT
2012
·
Raghuveer Singh Mali
, Peilin Ma
, et al.
·
Blood
·
55
Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN
2023
·
Jeff P. Sharman
, Miklos Egyed
, et al.
·
Blood
·
52
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN
2025
·
Jeff P. Sharman
, Miklos Egyed
, et al.
·
Blood
·
51
PDF
Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib
2024
·
Jennifer A. Woyach
, Daniel Jones
, et al.
·
Blood
·
51
Pak and Rac GTPases promote oncogenic KIT–induced neoplasms
2013
·
Holly Martin
, Raghuveer Singh Mali
, et al.
·
Journal of Clinical Investigation
·
44
PDF
Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression
2020
·
Alison R. Walker
, John C. Byrd
, et al.
·
Clinical Cancer Research
·
40
PDF
Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma
2019
·
Xiaojing Wang
, Wesley Blackaby
, et al.
·
Journal of Medicinal Chemistry
·
40
The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma
2013
·
V Munugalavadla
, S Mariathasan
, et al.
·
Oncogene
·
40
Genetic and pharmacologic evidence implicating the p85α, but not p85β, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis
2007
·
Veerendra Munugalavadla
, Emily C. Sims
, et al.
·
Blood
·
38
PDF
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
2020
·
Tian Zhang
, Michael R. Harrison
, et al.
·
Cancer
·
35
PDF
FAK and p38-MAP Kinase-Dependent Activation of Apoptosis and Caspase-3 in Retinal Endothelial Cells by α1(IV)NC1
2009
·
Chandra S. Boosani
, Narasimharao Nalabothula
, et al.
·
Investigative Ophthalmology & Visual Science
·
35
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study
2021
·
Matthew H. Taylor
, Courtney B. Betts
, et al.
·
Clinical Cancer Research
·
33
Show more works
View as search
Works count:
167
Citation count:
3,098
H-index:
29
I10-index:
57
Year
Topic
Type
